Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5129 - Telomere Associated Variables and their potential in CLL prognosis


11 Sep 2017


Poster display session


Translational Research


Nuria De Pedro


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


N. De Pedro1, J.C. Estrada1, M. Chiesa2, M. Diez1, I. Garcia3, R. González3, B. Garcia3, J. García1, L. Esteban4, L. Otero3, P. Najarro5

Author affiliations

  • 1 R&d, Life Length, 28010 - Madrid/ES
  • 2 Translational Research, GEICAM- Spanish Breast Cancer Group, Madrid/ES
  • 3 R&d, Life Length, Madrid/ES
  • 4 Clinical Department, Life Length, 28010 - Madrid/ES
  • 5 Clinical Department, Life Length, Madrid/ES


Abstract 5129


The molecular mechanisms that determine disease progression and evolution in CLL are not completely known. Telomeres are usually short in CLL and their attrition may contribute to disease evolution. In addition, telomerase activity (TA) levels have also been associated with prognosis and response to treatment. In order to integrate telomere associated variables (TAV) in CLL disease management further studies with robust methodology are required.


Purified peripheral CD19 (+) B-cells from 19 healthy donors and 42 CLLs in different stages of disease were obtained from the National Bank of DNA (Salamanca, Spain). Samples were tested to determine full telomere length (TL) distribution- including percentage of short telomeres by a high throughput quantitative fluorescence in situ hybridization (HT-Q-FISH) technique. TA by Quantitative Telomere Repeat Amplification Protocol (Q-TRAP) was also quantified. Full statistical analysis of the results in the context of the clinical history of the patients was performed.


Data from the pilot, retrospective study stablished strong correlations between key CLL variables and the severity of the disease. Overall, TL was shorter and TA presented higher values compared to normal age-matched subjects. Interestingly longer TL was observed for all CLL patients with somatic hyper-mutation (SHM) that in turn, was associated with better prognosis. Concomitantly, TA was elevated in those patients with no SHM and was linked to poor response to treatment and negative prognosis. The percentage of short telomeres was significantly higher for Binet C/Rai III and IV cases.


The use of reliable technologies to measure TAV should be integrated during early diagnostic in CLL to enhance the ability to predict disease evolution. This will require larger, prospective, longitudinal clinical studies.

Clinical trial identification

Legal entity responsible for the study

Life Length S.L.


Life Length S.L.


N. De Pedro, M. Diez, I. Garcia, R. González, B. Garcia, L. Esteban, L. Otero, P. Najarro, J.C. Estrada, J. García: Employee of Life Length. M. Chiesa: Former employee of Life Length.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.